romosozumab-aqqg (Evenity) - www.westernhealth.com

OFFICE ADMINISTRATION - INJECTION

Treatment of osteoporosis in postmenopausal women
- At high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, OR
- Patients who have failed or are intolerant to other available osteoporosis therapy

Patient is a postmenopausal female
One of the following (1, 2, or 3):
- 1) T-score less than or equal to -2.5SD, OR
- 2) Evidence of osteoporotic fracture or a fragility fracture, OR
- 3) Low bone mass and the physician determines that the patient is at high risk for fracture as evident by chart notes, AND
One of the following (A, B, C, D, or E):
- A)Patient had an inadequate response, as evidenced by documented worsening BMD, following at least one year of therapy with a bisphosphonate AND an additional year of treatment with Prolia, OR
- B)Patient had a non-traumatic fracture while on bisphosphonate therapy or Prolia, OR
- C)Patient had an intolerable side effect or contraindication to both oral and IV bisphosphonate therapy AND an intolerable side effect or contraindication to Prolia, OR
- D)Patient has tried ibandronate injection or zoledronic acid injection, OR
- E)Patient has severe renal impairment or chronic kidney disease, AND
Patient has received no more than 12 monthly doses during this therapy course, AND
Patient does not have hypocalcemia, AND
Patient did not have a myocardial infarction or stroke within the preceding year

All non-FDA approved uses not listed in the approved indications
Combination therapy with a bisphosphonate, Prolia, Forteo, Tymlos, Evista or calcitonin

Recommended dose is 210 mg (2 syringes) administered subcutaneously once every month for a duration of 12 months.

Last review date: July 16, 2019